ZME Science on MSN
Inside the Human Gene Editing Boom Driven by CRISPR Reshaping Everything From Medicine to Food
CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
15hOpinion
What James Watson got wrong about DNA
Sohini Ramachandran is a professor of biology, data science, and computer science at Brown University. C. Brandon Ogbunu is ...
5hon MSNOpinion
Ethics should lead, not play catch-up, expert emphasizes as Japan panel OKs making human embryos from stem cells
A leading bioethicist at Hiroshima University is calling for an anticipatory, rather than reactive, approach to ethics after ...
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.
The discovery of the DNA structure sparked a flurry of new research, birthing fields like molecular biology, biotechnology, ...
The immune system faces a delicate balancing act: it must be aggressive enough to fight infections and cancer, yet restrained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback